Feature | July 15, 2011| Dave Fornell

The Latest Developments in Cardiovascular Technology

As part of its efforts to expand integration of intravascular ultrasound (IVUS) image guidance with cath lab treatment devices, Volcano Corp. recently announced a supply agreement with ev3, a Covidien company. Volcano will supply its IVUS technology for use in ev3’s TurboHawk plaque excision (atherectomy) systems.


Volcano developed an IVUS-guided balloon catheter, the Vibe RX, which is available in Europe. The company plans to partner with other vendors to create a line of IVUS-guided therapy solutions.


Integrated FFR/OCT Unveiled
The world’s first system to integrate the functional and anatomical modalities of fractional flow reserve (FFR) and optical coherence tomography (OCT) into one platform was highlighted by St. Jude Medical in May at the Paris Course on Revascularization (EuroPCR) 2011. The Ilumien system enables OCT imaging with the third-generation DragonFly OCT catheter, and FFR measurement through wireless connections, which simplify set-up and measurement through the elimination of connecting cables. The combined technology offers percutaneous coronary intervention (PCI) optimization that helps physicians determine if therapeutic intervention is necessary. The Ilumien is pending European CE mark approval.


FDA Advisory Panel to Review Sapien
A U.S. Food and Drug Administration (FDA) advisory panel is scheduled to review Edwards Lifesciences’ premarket approval (PMA) application for the Sapien transcatheter heart valve on July 20. Edwards submitted a PMA application in the fall of 2010 based on data from the inoperable cohort (Cohort B) of the PARTNER Trial, for approval of this therapy in the treatment of inoperable patients with severe aortic stenosis.  


If cleared for commercial use, it would become the first transcatheter aortic valve replacement device in the United States. Transcatheter valve replacement is expected to eventually replace the current standard of open-heart valve replacement surgery.
So far, only one transcatheter valve has been cleared by the FDA – the Medtronic Melody pulmonary valve, which was cleared under a humanitarian device exemption in early 2010.


Medtronic also entered U.S trials for its CoreValve transcatheter aortic valve in late 2010.


FDA Worried About Japanese Devices
The U.S. Food and Drug Administration (FDA) is warning U.S. medical device vendors to beware of possible safety concerns and radioactive contamination of medical devices and components coming from Japan. The FDA said Japan is a critical participant in the global medical device market, but this industry was heavily impacted by the massive March 11, 2011 earthquake and tsunami. The FDA’s Center for Devices and Radiological Health (CDRH) and Center for Biologics Evaluation and Research (CBER) is raising concerns about possible effects these events may have on medical devices, electronic products and device components intended for the U.S. market
Neither CDRH nor CBER has been notified of any defective product or serious adverse events associated with the use of a device related to this disaster. However, given the extent of the devastation, both have concerns about manufacturing conditions as a result of the disaster that could impact the safety and effectiveness of Japanese medical devices. These concerns include radioactive contamination, use of contaminated water, compromise in sterile products during or after production, compromised reliability of product performance (e.g., electrical connectors, microprocessors, alarms, sensors), and damaged and/or disrupted medical device manufacturing facilities.
To read more, visit www.dicardiology.net/article/fda-worries-about-safety-japanese-medical-devices-following-earthquake-tsunami

2011 Best in KLAS Awards
KLAS announced the release of their highly anticipated “2011 Top 20 Best in KLAS Awards: Medical Equipment & Infrastructure” report. The awards are based on data from customer surveys of hospital and clinic executives, administrators, physicians, nurses, clinicians, and other directors and managers interacting with healthcare equipment and infrastructure solutions. Winners applicable to cardiac imaging included:
• Computed Tomography (CT) - 64-slice+: Toshiba Aquilion One
• Magnetic Resonance (MR) - 3.0T: Siemens Magnetom Verio
• MR - 1.5T: Toshiba Vantage
• Ultrasound - General Imaging: GE Healthcare Logiq E9
• Ultrasound - Cardiovascular: GE Healthcare Vivid E9 and the Toshiba Aplio

Related Content

Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve
News | Heart Valve Technology| May 24, 2017
May 24, 2017 — Late-breaking data presented at EuroPCR 2017 demonstrating excellent clinical outcomes for...
Nearly One-Quarter of Patients Say Mechanical Heart Valve Disturbs Sleep
News | Heart Valve Technology| May 19, 2017
Nearly one-quarter of patients with a mechanical heart valve say it disturbs their sleep, according to research...
Analysis Looks at Role Type of Valve Plays in Patient Outcomes Post-TAVR
News | Heart Valve Technology| May 15, 2017
For patients who undergo transcatheter aortic valve replacement (TAVR), their risk factors, not the type of valve used...
Baylor Jack and Jane Hamilton Heart and Vascular Hospital Implants CoreValve Evolut Pro Valve
News | Heart Valve Technology| May 03, 2017
The Baylor Jack and Jane Hamilton Heart and Vascular Hospital (BHVH) transcatheter aortic valve replacement (TAVR) team...
AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
News | Left Atrial Appendage (LAA) Occluders| April 25, 2017
AtriCure Inc. announced it has sold more than 100,000 AtriClip Left Atrial Appendage Exclusion System devices worldwide...
Alabama Medical Center First in Southeast to Offer CoreValve Evolut Pro TAVR Device
News | Heart Valve Technology| April 20, 2017
The Structural Heart Program at Princeton Baptist Medical Center, (Birmingham, Ala.) recently became the first center...
Updated AATS Guidelines Help Cardiovascular Surgeons Navigate Challenges of Managing Ischemic Mitral Regurgitation
News | Heart Valve Technology| April 20, 2017
April 20, 2017 — Mitral regurgitation can occur in up to 50 percent of patients with ischemic heart disease and even
PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device
News | Embolic Protection Devices| April 11, 2017
Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device...
Boston Scientific is buying TAVI valve maker Symetis, which has European approval for its Acurate Neo valve

The Symetis Acurate Neo TAVI valve.

News | Heart Valve Technology| April 11, 2017
April 10, 2017 — Boston Scientific recently announced a $435 million cash deal to acquire Symetis SA, a privately-hel
ASE, EACVI, focused update document, aortic stenosis, AS, echocardiography, new classification scheme
News | Cardiovascular Ultrasound| April 03, 2017
The American Society of Echocardiography (ASE) and the European Association of Cardiovascular Imaging (EACVI) have...
Overlay Init